460 related articles for article (PubMed ID: 16954476)
1. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
Ishii Y; Pirkmaier A; Alvarez JV; Frank DA; Keselman I; Logothetis D; Mandeli J; O'Connell MJ; Waxman S; Germain D
J Natl Cancer Inst; 2006 Sep; 98(17):1238-47. PubMed ID: 16954476
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
Zhang X; Zhang J; Wang L; Wei H; Tian Z
BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
[TBL] [Abstract][Full Text] [Related]
5. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
8. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
[TBL] [Abstract][Full Text] [Related]
9. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
10. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
11. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.
Gritsko T; Williams A; Turkson J; Kaneko S; Bowman T; Huang M; Nam S; Eweis I; Diaz N; Sullivan D; Yoder S; Enkemann S; Eschrich S; Lee JH; Beam CA; Cheng J; Minton S; Muro-Cacho CA; Jove R
Clin Cancer Res; 2006 Jan; 12(1):11-9. PubMed ID: 16397018
[TBL] [Abstract][Full Text] [Related]
12. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
Selvendiran K; Koga H; Ueno T; Yoshida T; Maeyama M; Torimura T; Yano H; Kojiro M; Sata M
Cancer Res; 2006 May; 66(9):4826-34. PubMed ID: 16651438
[TBL] [Abstract][Full Text] [Related]
13. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
14. Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development.
Young N; Hahn CN; Poh A; Dong C; Wilhelm D; Olsson J; Muscat GE; Parsons P; Gamble JR; Koopman P
J Natl Cancer Inst; 2006 Aug; 98(15):1060-7. PubMed ID: 16882943
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.
Leslie K; Lang C; Devgan G; Azare J; Berishaj M; Gerald W; Kim YB; Paz K; Darnell JE; Albanese C; Sakamaki T; Pestell R; Bromberg J
Cancer Res; 2006 Mar; 66(5):2544-52. PubMed ID: 16510571
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B.
Joung YH; Lim EJ; Kim MS; Lim SD; Yoon SY; Lim YC; Yoo YB; Ye SK; Park T; Chung IM; Bae KY; Yang YM
Int J Oncol; 2008 Sep; 33(3):477-84. PubMed ID: 18695876
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Ko BS; Chang TC; Chen CH; Liu CC; Kuo CC; Hsu C; Shen YC; Shen TL; Golubovskaya VM; Chang CC; Shyue SK; Liou JY
Life Sci; 2010 Jan; 86(5-6):199-206. PubMed ID: 20006625
[TBL] [Abstract][Full Text] [Related]
18. A plant oxylipin, 12-oxo-phytodienoic acid, inhibits proliferation of human breast cancer cells by targeting cyclin D1.
Altiok N; Mezzadra H; Patel P; Koyuturk M; Altiok S
Breast Cancer Res Treat; 2008 May; 109(2):315-23. PubMed ID: 17638069
[TBL] [Abstract][Full Text] [Related]
19. Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation.
Catalano S; Giordano C; Rizza P; Gu G; Barone I; Bonofiglio D; Giordano F; Malivindi R; Gaccione D; Lanzino M; De Amicis F; Andò S
J Cell Physiol; 2009 Mar; 218(3):490-500. PubMed ID: 18988190
[TBL] [Abstract][Full Text] [Related]
20. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
Yerlikaya A; Erin N
Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
